Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases

References

• Czaja AJ. The variant forms of autoimmune hepatitis. Ann. Intern. Med.125(7), 588–598 (1996).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology28(2), 360–365 (1998).
   PubMed Web of Science ®Google Scholar
• Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology18(1), 10–15 (1993).
   PubMed Web of Science ®Google Scholar
• Sanchez-Pobre P, Castellano G, Colina F et al. Antimitochondrial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis? J. Clin. Gastroenterol.23(3), 191–198 (1996).
   PubMedGoogle Scholar
• Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML. An atypical presentation for primary sclerosing cholangitis. Dig. Dis. Sci.42(10), 2009–2016 (1997).
   PubMedGoogle Scholar
• Heathcote J. Variant syndromes of autoimmune hepatitis. Clin. Liver Dis.6(3), 669–684 (2002).
   PubMedGoogle Scholar
• Poupon R. Autoimmune overlapping syndromes. Clin. Liver Dis.7(4), 865–878 (2003).
   PubMedGoogle Scholar
• Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver4(2), 105–116 (1984).
   PubMedGoogle Scholar
• Burak KW, Urbanski SJ, Swain MG. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig. Dis. Sci.46(9), 2043–2047 (2001).
   PubMedGoogle Scholar
• Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet362(9377), 53–61 (2003).
   PubMed Web of Science ®Google Scholar
• LaRusso NF, Shneider BL, Black D et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology44(3), 746–764 (2006).
   PubMed Web of Science ®Google Scholar
• Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology33(4), 994–1002 (2001).
   PubMed Web of Science ®Google Scholar
• Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin. Liver Dis.6(3), 685–705 (2002).
   PubMedGoogle Scholar
• Scheuer PJ. Ludwig Symposium on biliary disorders – part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin. Proc.73(2), 179–183 (1998).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int.24(4), 322–329 (2004).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J. Clin. Gastroenterol.37(4), 315–329 (2003).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology120(1), 239–249 (2001).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology105(5), 1522–1528 (1993).
   PubMedGoogle Scholar
• Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J. Hepatol.30(3), 394–401 (1999).
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin. Liver Dis.25(3), 298–310 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N. Engl. J. Med.353(12), 1261–1273 (2005).
   PubMed Web of Science ®Google Scholar
• Tan EM, Feltkamp TE, Smolen JS et al. Range of antinuclear antibodies in ‘healthy’ individuals. Arthritis Rheum.40(9), 1601–1611 (1997).
   PubMed Web of Science ®Google Scholar
• Chazouilleres O, Wendum D, Serfaty L et al. Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology28(2), 296–301 (1998).
   PubMed Web of Science ®Google Scholar
• Lohse AW, zum Buschenfelde KH, Franz B et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology29(4), 1078–1084 (1999).
   PubMed Web of Science ®Google Scholar
• Muratori L, Cassani F, Pappas G et al. The hepatitic/cholestatic ‘overlap’ syndrome: an Italian experience. Autoimmunity35(8), 565–568 (2002).
   PubMed Web of Science ®Google Scholar
• Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology44(1), 85–90 (2006).
   PubMedGoogle Scholar
• Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J. Hepatol.44(2), 400–406 (2006).
   PubMed Web of Science ®Google Scholar
• Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology31(4), 1005–1013 (2000).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology106(5), 1284–1290 (1994).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology110(5), 1515–1518 (1996).
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Cauch-Dudek K et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology113(3), 884–890 (1997).
   PubMed Web of Science ®Google Scholar
• Angulo P, Lindor KD, Therneau TM et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver19(2), 115–121 (1999).
   PubMedGoogle Scholar
• Corpechot C, Carrat F, Bahr A et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology128(2), 297–303 (2005).
   PubMed Web of Science ®Google Scholar
• ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-year cohort study involving 297 patients. Am. J. Gastroenterol.101(9), 2044–2050 (2006).
   PubMed Web of Science ®Google Scholar
• Poupon R, Chretien Y, Poupon RE et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet1(8537), 834–836 (1987).
   PubMed Web of Science ®Google Scholar
• Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet354(9184), 1053–1060 (1999).
   PubMed Web of Science ®Google Scholar
• Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using bayesian approach as sensitivity analyses. Am. J. Gastroenterol.102(8), 1799–1807 (2007).
   PubMed Web of Science ®Google Scholar
• Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. QJ Med.40(158), 159–185 (1971).
   PubMedGoogle Scholar
• Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology63(5), 820–833 (1972).
   PubMed Web of Science ®Google Scholar
• Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet1(7806), 735–737 (1973).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology30(6), 1381–1386 (1999).
   PubMed Web of Science ®Google Scholar
• Mitchison HC, Palmer JM, Bassendine MF et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J. Hepatol.15(3), 336–344 (1992).
   PubMed Web of Science ®Google Scholar
• Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther.8(6), 585–590 (1994).
   PubMed Web of Science ®Google Scholar
• Angulo P, Jorgensen RA, Keach JC et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology31(2), 318–323 (2000).
   PubMed Web of Science ®Google Scholar
• Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology70(5 Pt 1), 656–660 (1976).
   PubMed Web of Science ®Google Scholar
• Christensen E, Neuberger J, Crowe J et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology89(5), 1084–1091 (1985).
   PubMed Web of Science ®Google Scholar
• Crowe J, Christensen E, Smith M et al. Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology78(5 Pt 1), 1005–1010 (1980).
   PubMed Web of Science ®Google Scholar
• Wolfhagen FH, van Hoogstraten HJ, van Buuren HR et al. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J. Hepatol.29(5), 736–742 (1998).
   PubMed Web of Science ®Google Scholar
• Leuschner M, Maier KP, Schlichting J et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology117(4), 918–925 (1999).
   PubMed Web of Science ®Google Scholar
• Rautiainen H, Karkkainen P, Karvonen AL et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology41(4), 747–752 (2005).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep.1(1), 63–70 (1999).
   PubMedGoogle Scholar
• Czaja AJ. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J. Hepatol.44(2), 251–252 (2006).
   PubMedGoogle Scholar
• Czaja AJ. Current concepts in autoimmune hepatitis. Ann. Hepatol.4(1), 6–24 (2005).
   PubMedGoogle Scholar
• Vento S, Garofano T, Di Perri G et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet337(8751), 1183–1187 (1991).
   PubMed Web of Science ®Google Scholar
• Vento S, Di Perri G, Luzzati R et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet335(8694), 921–922 (1990).
   PubMedGoogle Scholar
• Vento S, Cainelli F, Ferraro T, Concia E. Autoimmune hepatitis type 1 after measles. Am. J. Gastroenterol.91(12), 2618–2620 (1996).
   PubMedGoogle Scholar
• Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br. Med. J.312(7024), 169–172 (1996).
   PubMed Web of Science ®Google Scholar
• Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus12(5), 409–412 (2003).
   PubMed Web of Science ®Google Scholar
• Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur. J. Gastroenterol. Hepatol.15(8), 921–924 (2003).
   PubMed Web of Science ®Google Scholar
• Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur. J. Gastroenterol. Hepatol.17(5), 589–590 (2005).
   PubMed Web of Science ®Google Scholar
• Alla V, Abraham J, Siddiqui J et al. Autoimmune hepatitis triggered by statins. J. Clin. Gastroenterol.40(8), 757–761 (2006).
   PubMed Web of Science ®Google Scholar
• Joshi S, Cauch-Dudek K, Wanless IR et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology35(2), 409–413 (2002).
   PubMedGoogle Scholar
• Heurgue A, Vitry F, Diebold MD et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol. Clin. Biol.31(1), 17–25 (2007).
   PubMedGoogle Scholar
• Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am. J. Gastroenterol.97(5), 1191–1197 (2002).
   PubMedGoogle Scholar
• Suzuki Y, Arase Y, Ikeda K et al. Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. J. Gastroenterol. Hepatol.19(6), 699–706 (2004).
   PubMedGoogle Scholar
• Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol.31(5), 929–938 (1999).
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Terada R, Okamoto R et al. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease. J. Gastroenterol.38(1), 52–59 (2003).
   PubMed Web of Science ®Google Scholar
• Gunsar F, Akarca US, Ersoz G et al. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis–autoimmune hepatitis overlap syndrome. Hepatogastroenterology49(47), 1195–1200 (2002).
   PubMedGoogle Scholar
• Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology18(4), 998–1005 (1993).
   PubMed Web of Science ®Google Scholar
• Schramm C, Lohse AW. Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis. Clin. Rev. Allergy Immunol.28(2), 105–114 (2005).
   PubMedGoogle Scholar
• Chazouilleres O, Poupon R. Ursodeoxycholic acid and primary biliary cirrhosis with features of autoimmune hepatitis. Hepatology36(4 Pt 1), 1026–1027 (2002).
   PubMedGoogle Scholar
• Gheorghe L, Iacob S, Gheorghe C et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur. J. Gastroenterol. Hepatol.16(6), 585–592 (2004).
   PubMedGoogle Scholar
• Heathcote EJ. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am. J. Gastroenterol.97(5), 1090–1092 (2002).
   PubMedGoogle Scholar
• Duclos-Vallee JC, Hadengue A, Ganne-Carrie N et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig. Dis. Sci.40(5), 1069–1073 (1995).
   PubMedGoogle Scholar
• Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am. J. Gastroenterol.102(6), 1244–1250 (2007).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity35(8), 475–483 (2002).
   PubMed Web of Science ®Google Scholar
• el-Shabrawi M, Wilkinson ML, Portmann B et al. Primary sclerosing cholangitis in childhood. Gastroenterology92(5 Pt 1), 1226–1235 (1987).
   PubMedGoogle Scholar
• Mieli-Vergani G, Lobo-Yeo A, McFarlane BM et al. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology9(2), 198–203 (1989).
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Chait P, Wade JA et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology22(5), 1415–1422 (1995).
   PubMed Web of Science ®Google Scholar
• Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig. Dis. Sci.37(10), 1606–1611 (1992).
   PubMedGoogle Scholar
• McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am. J. Gastroenterol.93(5), 777–784 (1998).
   PubMed Web of Science ®Google Scholar
• Gohlke F, Lohse AW, Dienes HP et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J. Hepatol.24(6), 699–705 (1996).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig. Dis. Sci.46(1), 140–147 (2001).
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Doherty DG, Hayllar KM et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology13(4), 701–706 (1991).
   PubMed Web of Science ®Google Scholar
• Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. Hepatology20(1 Pt 1), 225–239 (1994).
   PubMedGoogle Scholar
• Boberg KM, Fausa O, Haaland T et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology23(6), 1369–1376 (1996).
   PubMed Web of Science ®Google Scholar
• Terjung B, Spengler U, Sauerbruch T, Worman HJ. ‘Atypical p-ANCA’ in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology119(2), 310–322 (2000).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology36(2), 479–497 (2002).
   PubMed Web of Science ®Google Scholar
• Ma Y, Okamoto M, Thomas MG et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology35(3), 658–664 (2002).
   PubMed Web of Science ®Google Scholar
• Baeres M, Herkel J, Czaja AJ et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut51(2), 259–264 (2002).
   PubMed Web of Science ®Google Scholar
• Vergani D, Mieli-Vergani G. Autoimmune hepatitis and sclerosing cholangitis. Autoimmunity37(4), 329–332 (2004).
   PubMed Web of Science ®Google Scholar
• Chazouilleres O. Diagnosis of primary sclerosing cholangitis–autoimmune hepatitis overlap syndrome: to score or not to score? J. Hepatol.33(4), 661–663 (2000).
   PubMedGoogle Scholar
• Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful? Clin. Gastroenterol. Hepatol.2(10), 935–940 (2004).
   PubMed Web of Science ®Google Scholar
• van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J. Hepatol.33(4), 543–548 (2000).
   PubMedGoogle Scholar
• Czaja A, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig. Dis. Sci.41(2), 305–314 (1996).
   PubMed Web of Science ®Google Scholar
• Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J. Hepatol.33(4), 537–542 (2000).
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology33(3), 544–553 (2001).
   PubMed Web of Science ®Google Scholar
• Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology36(6), 1393–1399 (2002).
   PubMed Web of Science ®Google Scholar
• Hatzis GS, Vassiliou VA, Delladetsima JK. Overlap syndrome of primary sclerosing cholangitis and autoimmune hepatitis. Eur. J. Gastroenterol. Hepatol.13(2), 203–206 (2001).
   PubMedGoogle Scholar
• Domschke W, Klein R, Terracciano LM et al. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: a follow up study over 14 years. Liver20(4), 340–345 (2000).
   PubMedGoogle Scholar
• Hong-Curtis J, Yeh MM, Jain D, Lee JH. Rapid progression of autoimmune hepatitis in the background of primary sclerosing cholangitis. J. Clin. Gastroenterol.38(10), 906–909 (2004).
   PubMedGoogle Scholar
• Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J. Hepatol.14(2–3), 325–331 (1992).
   PubMed Web of Science ®Google Scholar
• Wurbs D, Klein R, Terracciano LM, Berg PA, Bianchi L. A 28-year-old woman with a combined hepatitic/cholestatic syndrome. Hepatology22(5), 1598–1605 (1995).
   PubMedGoogle Scholar
• Lawrence SP, Sherman KE, Lawson JM, Goodman ZD. A 39 year old man with chronic hepatitis. Semin. Liver Dis.14(1), 97–105 (1994).
   PubMedGoogle Scholar
• Floreani A, Rizzotto ER, Ferrara F et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am. J. Gastroenterol.100(7), 1516–1522 (2005).
   PubMed Web of Science ®Google Scholar